59th Annual ASH Meeting - Bing Center Poster Presentations

The 59th Annual ASH meeting & exposition was held was held December 9-12, 2017 in Atlanta, GA. The following are the 16 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.

Click on the poster to download a full size PDF version. For more information about ASH-2017, please visit http://www.hematology.org/Annual-Meeting/

 

Acquired Von Willebrand Disease in Patients with Waldenstrom Macroglobulinemia

Acquired Von Willebrand Disease in Patients with Waldenstrom Macroglobulinemia

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstrom's Macroglobulinemia and ABC DLBCL Cells

Aberrant HCK Survival Signaling By Mutated MYD88 Requires PAX5 in Waldenstrom's Macroglobulinemia and ABC DLBCL Cells

Xia Liu, Jiaji Chen, Manit Munshi, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary Hunter, Christopher Patterson, Robert Manning, Philip Brodsky, Joshua Gustine, Patricia Severns, Toni Dubeau, Jorge Castillo, Steven Treon, and Guang Yang

 

Mutated MYD88 Homozygosity Is Increased in Previously Treated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure

Mutated MYD88 Homozygosity Is Increased in Previously Trated Patients with Waldenstrom's Macroglobulinemia, and Associates with CXCR4 Mutation Status and Ibrutinib Exposure

Nickolas Tsakmaklis, Lian Xu, Joshua Gustine, Robert J. Manning, Guang Yang, Jie Chen, Xia Liu, Jiaji Chen, Maria Demos, Gloria G. Chan, Christopher J. Patterson, Jorge J. Castillo, Steven P. Treon and Zachary R. Hunter

 

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrom's Macroglobulinemia

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenstrom's Macroglobulinemia

Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline WM

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline WM

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni E. Dubeau, Patricia Severns, Steven P. Treon

 

Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in WM

Mutated MYD88 Activates the BCR Component SYK and Provides a Rationale Therapeutic Target in WM

Manit Munshi, Xia Liu, Jiaji Chen, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Gloria Chan, Zachary R. Hunter, Christopher J. Patterson, Robert Manning, Philip Brodsky, Joshua Gustine, Patricia Severns, Toni Dubeau, Jorge J. Castillo, Steven P. Treon, and Guang Yang

 

Long-Term Follow-Up of Previously Treated Patients Who Received Ibrutinib for Symptomatic WM: Update of Pivotal Clinical Trial

Long-Term Follow-Up of Previously Treated Patients Who Received Ibrutinib for Symptomatic WM: Update of Pivotal Clinical Trial

Steven P. Treon, Kirsten Meid, Joshua Gustine, Kurt S. Bantilan, Toni Dubeau, Patricia Severns, Guang Yang, Lian Xu, Christopher Patterson, Irene M. Ghobrial, Jacob Laubach, Zachary R. Hunter, Jorge J. Castillo, Maria L. Palomba, and Ranjana H. Advani.

 

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic WM

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic WM

Steven P. Treon, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Christopher Patterson, Lian Xu, Guang Yang, Maria Demos, Amanda Kofides, Jiaji Chen, Manit Munshi, Nickolas Tsakmaklis, Gloria Chan, Andrew Yee, Noopur Raje, Elizabeth O'Donnell, Zachary R. Hunter, and Jorge Castillo

 

Long-Term Analysis of a Prospective Phase II Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in WM

Long-Term Analysis of a Prospective Phase II Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in WM

Kirsten Meid, MPH, , Toni Dubeau, NP, Patricia Severns, NP, Joshua Gustine, MPH, Irene M. Ghobrial, MD, Jorge J. Castillo, MD, and, Steven P. Treon, MD, PhD, Bing Center for Waldenstrom’s Macroglobulinemia at the Dana-Farber

 

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in WM

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in WM

Zachary R. Hunter, Nickolas Tsakmaklis, Lian Xu, Maria Demos, Amanda Kofides, Gloria G. Chan, Jiaji Chen, Manit Munshi, Xia Liu, Joshua Gustine, Christopher J. Patterson, Toni Dubeau, Patricia Severns, Jorge Castillo, Guang Yang, Nikhil Munshi, Kenneth Anderson and Steven P. Treon

 

MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in WM

MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in WM

Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Lu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Jiaji Chen, Christopher J. Patterson, Toni Dubeau, Patricia Severns, and Jorge J. Castillo.

 

The Genomic Landscape of MYD88 Wild-Type WM Is characterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2

The Genomic Landscape of MYD88 Wild-Type WM Is characterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2

Zachary Hunter, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Lian Xu, Gloria Chan, Jiaji Chen, Manit Munsh, Xia Liu, Joshua Gustine, Christopher Patterson, Toni Dubeau, Patricia Severns, Jorge J. Castillo, Guang Yang and Steven P Treon

 

Survival Rates and Clinical Characteristics of Young Patients with WM

Survival Rates and Clinical Characteristics of Young Patients with WM

Amaara Babwah, MS, Joshua Gustine, MPH, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P. Treon, MD, PhD and Jorge J. Castillo, MD

 

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated WM

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated WM

Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, M. Lia Palomba, Ranjana H. Advani, Steven P. Treon, and Jorge J. Castillo

 

Patient-reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome

Patient-reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome

Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, and Steven P. Treon

 

Differential Diagnosis of Suspected MYD88 Wild_Type WM Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Differential Diagnosis of Suspected MYD88 Wild_Type WM Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Steven P. Treon, Zachary R. Hunter, Joshua Gustine, Kirsten Meid, Lian Xu, Xia Lu, Guang Yang, Manit Munshi, Robert Manning, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, Jiaji Chen, Christopher J. Patterson, Toni Dubeau, Patricia Severns, and Jorge Castillo.